









Markets
/
Stocks
/
nasdaq-apm
/

Aptorum Group Ltd

APM

1.400USD

-0.010-0.71%

Market hours （ET）Quotes delayed by 15 min

10.00MMarket Cap

--P/E TTM



Aptorum Group Ltd

1.400

-0.010-0.71%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Aptorum Group Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aptorum Group Ltd's Score

Industry at a Glance

Industry Ranking

301 / 501

Overall Ranking

570 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Aptorum Group Ltd Highlights

StrengthsRisks

Aptorum Group Limited is a United Kingdom-based clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.

Overvalued

The company’s latest PE is -1.93, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 43.95K shares, decreasing 65.40% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 6.16.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Aptorum Group Ltd's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 7.38, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -1.93, which is -63.84% below the recent high of -0.70 and -1734.40% above the recent low of -35.39.

Score

Industry at a Glance

Previous score

7.38

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 301/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.04.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 6.42, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 2.27 and the support level at 1.08, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.49

Change

-0.07

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.024

Sell

RSI(14)

37.443

Neutral

STOCH(KDJ)(9,3,3)

17.110

Oversold

ATR(14)

0.090

High Vlolatility

CCI(14)

-158.708

Sell

Williams %R

86.885

Oversold

TRIX(12,20)

-1.216

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

1.440

Sell

MA10

1.467

Sell

MA20

1.606

Sell

MA50

1.810

Sell

MA100

1.601

Sell

MA200

1.297

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

CGY Investments Ltd

533.58K

Jurchen Investment Corp

370.31K

Huen (Ian)

137.66K

Geode Capital Management, L.L.C.

37.45K

+1.36%

Osaic Holdings, Inc.

5.50K

Citi Investment Research (US)

995.00

+5136.84%

SBI Securities Co., Ltd.

7.00

-89.55%

L1 Capital Global Opportunities Master Fund Ltd.

-100.00%

XTX Markets LLC

-100.00%

Morgan Stanley & Co. LLC

-100.00%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is -0.01. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.